H1N1 (Swine Influenza) - Drug Pipeline Landscape, 2023
Description
H1N1 (Swine Influenza) - Drug Pipeline Landscape, 2023
The H1N1 flu (swine flu) is primarily caused by the H1N1 strain of the flu (influenza) virus. It is a communicable viral illness causing upper and lower respiratory tract infections.
Swine flu H1N1 infects the cells that line nose, throat and lungs. The virus enters body when contaminated droplets are inhaled or transfer live virus from a contaminated surface to eyes, nose or mouth.
The most common symptoms of H1N1 infection include difficulty in breathing, chest pain, dizziness, nasal secretions, chills, fever, cough, sore throat, decreased appetite, and in some cases and lower respiratory tract disease.
Healthcare practitioners look for signs and symptoms of influenza, including H1N1 flu (swine flu) during the diagnosis. Laboratory tests like swab culture test, rapid flu test etc, can also be suggested for diagnosis.
There are several treatment options for swine influenza, most commonly antiviral drugs like oseltamivir zanamivir peramivir and baloxavir are used. Symptoms can be eased through lifestyle changes and home remedies like drinking plenty of water and using pain relievers.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the H1N1 (Swine Influenza) treatment such as Baloxavir marboxil, mRNA-1010, CD388 and others. Key players involved in the development of therapies to treat H1N1 (Swine Influenza) are Abzyme Therapeutics LLC, Blue Water Vaccines Inc, Cidara Therapeutics Inc, Genentech USA Inc, Moderna Inc and others. Two drugs are under late-stage Phase III clinical trials and eight drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical and Discovery stages of development.
In December 2022, Cidara Therapeutics announced issuance of first U.S patent for CD388.
Report Highlights
Global Insight Service's, H1N1 (Swine Influenza) - Drug Pipeline Landscape, 2023 report provides an overview of the H1N1 (Swine Influenza) pipeline drugs. This report covers detailed insights on H1N1 (Swine Influenza) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. H1N1 (Swine Influenza) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
The H1N1 flu (swine flu) is primarily caused by the H1N1 strain of the flu (influenza) virus. It is a communicable viral illness causing upper and lower respiratory tract infections.
Swine flu H1N1 infects the cells that line nose, throat and lungs. The virus enters body when contaminated droplets are inhaled or transfer live virus from a contaminated surface to eyes, nose or mouth.
The most common symptoms of H1N1 infection include difficulty in breathing, chest pain, dizziness, nasal secretions, chills, fever, cough, sore throat, decreased appetite, and in some cases and lower respiratory tract disease.
Healthcare practitioners look for signs and symptoms of influenza, including H1N1 flu (swine flu) during the diagnosis. Laboratory tests like swab culture test, rapid flu test etc, can also be suggested for diagnosis.
There are several treatment options for swine influenza, most commonly antiviral drugs like oseltamivir zanamivir peramivir and baloxavir are used. Symptoms can be eased through lifestyle changes and home remedies like drinking plenty of water and using pain relievers.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the H1N1 (Swine Influenza) treatment such as Baloxavir marboxil, mRNA-1010, CD388 and others. Key players involved in the development of therapies to treat H1N1 (Swine Influenza) are Abzyme Therapeutics LLC, Blue Water Vaccines Inc, Cidara Therapeutics Inc, Genentech USA Inc, Moderna Inc and others. Two drugs are under late-stage Phase III clinical trials and eight drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical and Discovery stages of development.
In December 2022, Cidara Therapeutics announced issuance of first U.S patent for CD388.
Report Highlights
Global Insight Service's, H1N1 (Swine Influenza) - Drug Pipeline Landscape, 2023 report provides an overview of the H1N1 (Swine Influenza) pipeline drugs. This report covers detailed insights on H1N1 (Swine Influenza) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. H1N1 (Swine Influenza) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
153 Pages
- 1. Introduction
- 1.1 H1N1 (Swine Influenza) - Pipeline Drugs, 2023 - Coverage
- 2.Disease Overview - H1N1 (Swine Influenza)
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3.H1N1 (Swine Influenza) - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4.Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5.Drug Profiles
- 5.1 Clinical Stage Drugs-Phase III
- 5.1.1 Baloxavir marboxil
- 5.1.2 mRNA-1010
- 5.2 Clinical Stage Drugs-Phase II
- 5.2.1 Adjuvanted Cell Culture Influenza Vaccine (aQIVc)
- 5.2.2 Adjuvanted FLU-v
- 5.2.3 CD388
- 5.2.4 DAS181
- 5.2.5 INNA-051
- 5.2.6 SAB-176
- 5.2.7 Seasonal Flu Vaccine
- 5.2.8 VIS410
- 5.3 Clinical Stage Drugs-Phase I
- 5.3.1 CODA-VAX H1N1
- 5.3.2 FLU SV Mrna
- 5.3.3 Influenza A Drug
- 5.3.4 Quadrivalent Influenza Vaccine
- 5.3.5 Trivalent influenza vaccine
- 5.3.6 UniFlu
- 5.4 Early Stage Drugs-Preclinical
- 5.4.1 AV5124
- 5.4.2 BWV-101
- 5.4.3 BWV-102
- 5.4.4 CBS1116
- 5.4.5 Drug for H1N1
- 5.4.6 EC-QIV
- 5.4.7 Flucide
- 5.4.8 H1N1 Flu Vaccine
- 5.4.9 Influenza A/B
- 5.4.10 Influenza Vaccine
- 5.4.11 Neuraminidase
- 5.4.12 R327
- 5.4.13 Nasal"
- 5.4.14 Tetravalent flu VLP vaccine
- 5.4.15 Vaccine
- 5.4.16 VMTX-001
- 5.5 Early Stage Drugs-Discovery
- 5.5.1 UMIN-101
- 6.Key Regulatory Designations
- 7.Key Deals
- 8.Key Upcoming Milestones
- 9.Key Companies Involved
- 9.1 Abzyme Therapeutics LLC
- 9.2 Ansun Biopharma Inc
- 9.3 Blue Water Vaccines Inc
- 9.4 BunyaVax BV
- 9.5 Chicago Biosolutions Inc
- 9.6 Cidara Therapeutics Inc
- 9.7 Cocrystal Pharma Inc
- 9.8 Codagenix, Inc
- 9.9 Collaborations Pharmaceuticals Inc
- 9.10 CSL Ltd
- 9.11 Curevac NV
- 9.12 Dnarx LLC
- 9.13 Emergent BioSolutions Inc
- 9.14 Ena Respiratory Pty Ltd
- 9.15 EpiVax Inc
- 9.16 Genentech USA Inc
- 9.17 Imutex Ltd
- 9.18 Jiangsu Ab&b Biotechnology Co Ltd
- 9.19 Medicago Inc
- 9.20 Moderna Inc
- 9.21 NanoViricides Inc
- 9.22 Recce Pharmaceuticals Ltd
- 9.23 SAb Biotherapeutics, Inc
- 9.24 Sciogen Inc
- 9.25 TechnoVax Inc
- 9.26 UMN Pharma Inc
- 9.27 Viramatix Sdn Bhd
- 9.28 Viriom Inc
- 9.29 Visterra, Inc.
- 9.30 Zosano Pharma Corp
- 10.Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11.Appendix
- List of Tables
- Table 1.2 Number of Products under Development by H1N1 (Swine Influenza)
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - Baloxavir marboxil/Genentech USA Inc
- Table 2.2 Clinical Trial Details - CD388/Cidara Therapeutics Inc
- Table 2.3 Clinical Trial Details - mRNA-1010/Moderna Inc
- Table 2.4 Clinical Trial Details - Adjuvanted Cell Culture Influenza Vaccine (aQIVc)/CSL Ltd
- Table 2.5 Clinical Trial Details - Adjuvanted FLU-v/Imutex Ltd
- Table 2.6 Clinical Trial Details - DAS181/Ansun Biopharma Inc
- Table 2.7 Clinical Trial Details - INNA-051/Ena Respiratory Pty Ltd
- Table 2.8 Clinical Trial Details - SAB-176/SAb Biotherapeutics, Inc
- Table 2.9 Clinical Trial Details - Seasonal Flu Vaccine/Medicago Inc
- Table 2.10 Clinical Trial Details - VIS410 /Visterra, Inc.
- Table 2.11 Clinical Trial Details - CODA-VAX H1N1/Codagenix, Inc
- Table 2.12 Clinical Trial Details - FLU SV Mrna/Curevac NV
- Table 2.13 Clinical Trial Details - Influenza A/Cocrystal Pharma Inc
- Table 2.14 Clinical Trial Details - Quadrivalent Influenza Vaccine/Jiangsu Ab&b Biotechnology Co Ltd
- Table 2.15 Clinical Trial Details - Trivalent influenza vaccine/Zosano Pharma Corp
- Table 2.16 Clinical Trial Details - UniFlu/Emergent BioSolutions Inc
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for H1N1 (Swine Influenza), 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for H1N1 (Swine Influenza), 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for H1N1 (Swine Influenza), 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for H1N1 (Swine Influenza), 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for H1N1 (Swine Influenza), 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
